Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,000 across all filing types
Latest filing 2024-11-20 Regulatory Filings
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
241119_PRESS RELEASE BIMZELX- US approval HS_CLEAN FINAL_.pdf
Regulatory Filings Classification · 1% confidence The document is a press release dated November 20, 2024, announcing that UCB received U.S. FDA approval for BIMZELX® (bimekizumab-bkzx) for treating moderate to severe hidradenitis suppurativa (HS). It details the clinical trial data (BE HEARD I and II), lists important safety information (ISI) for the U.S. market, and includes EU/EEA information. This type of announcement, detailing a significant regulatory event (FDA approval) and providing key clinical/safety context, is characteristic of an Earnings Release (ER) or a general press release announcing a major corporate/product milestone. Since it is a formal announcement of a key result/event rather than a comprehensive periodic report (10-K, IR) or a transcript (CT), 'ER' (Earnings Release) is the closest fit for a major corporate announcement, although 'RNS' (Regulatory Filings) is also plausible for a general regulatory update. Given the structure and focus on a major product approval, ER is often used for such significant news releases, even if not tied directly to quarterly earnings. However, since this is a specific regulatory approval announcement, and not explicitly tied to a quarterly financial period summary, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if such announcements are bundled there. Given the content is a major regulatory milestone announcement, and not a standard earnings report, RNS is the most appropriate fallback for a significant, non-periodic regulatory event announcement that doesn't fit other specific categories like DIV or CAP. I will classify it as RNS as it is a general regulatory announcement.
2024-11-20 English
18.11.24 - PR Transparency notification BlackRock.pdf
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'Transparency notification BlackRock, Inc.' and details changes in shareholding percentages, specifically noting that BlackRock, Inc.'s shareholding in UCB SA/NV 'increased and crossed the 5% threshold on 12 November 2024.' It provides detailed tables showing the number of voting rights and equivalent financial instruments held by various BlackRock affiliates, which is the core content of a major shareholding disclosure. This directly corresponds to the definition of Major Shareholding Notification (MRQ).
2024-11-18 English
18.11.24 - CdP Notification de transparence BlackRock.pdf
Major Shareholding Notification Classification · 1% confidence The document is titled "Notification de transparence BlackRock, Inc." and explicitly states that UCB SA received a transparency declaration from BlackRock, Inc. regarding an acquisition of voting shares that crossed the 5% threshold on November 12, 2024. This content directly relates to reporting changes in significant share ownership levels, which matches the definition for Major Shareholding Notification (MRQ). Although it is a formal notification, it is not a general regulatory filing (RNS) because a more specific category exists. It is not a Director's Dealing (DIRS) as it concerns a major institutional shareholder, not a director's personal transaction. The document details the exact number of shares and the percentage crossing the threshold.
2024-11-18 French
18.11.24 - PB Transparantieverklaring BlackRock.pdf
Director's Dealing Classification · 1% confidence The document is a 'Transparantieverklaring' (Transparency Declaration) from UCB NV, announcing that BlackRock, Inc. has crossed the 5% threshold of voting rights due to an acquisition of shares. This type of mandatory disclosure regarding changes in significant share ownership, especially crossing regulatory thresholds (like the 5% threshold mentioned, referencing Belgian law), directly corresponds to the definition of Major Shareholding Notification. The key indicators are: 1. Mention of 'belangrijke deelnemingen' (important shareholdings) and crossing a threshold (5%). 2. Detailed breakdown of voting rights and financial instruments held by the entity and its affiliates. 3. The document structure resembles a regulatory filing notification rather than a comprehensive financial report (10-K, IR) or a general press release (ER, RNS). Therefore, the classification is Major Shareholding Notification (MRQ).
2024-11-18 Dutch
241118 - PR Transparency notification BlackRock Final.pdf
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'Transparency notification BlackRock, Inc.' and details the change in BlackRock's shareholding in UCB SA/NV, specifically noting that the holding 'decreased and crossed the 5% threshold downwards' pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings. This content directly relates to reporting changes in significant share ownership, which matches the definition for Major Shareholding Notification (MRQ). It is not an earnings release, annual report, or a general regulatory filing (RNS), as it concerns a specific insider/major shareholder transaction disclosure.
2024-11-18 English
241118- CdP Notification de transparence BlackRock Final.pdf
Major Shareholding Notification Classification · 1% confidence The document is titled "Notification de transparence BlackRock, Inc." and explicitly states it is an announcement regarding a change in shareholding that crossed a threshold (5% threshold crossed downwards). It details the number of voting rights held by BlackRock and its related entities before and after the transaction, referencing Belgian transparency laws ("loi du 2 mai 2007 relative à la publicité des participations importantes"). This content directly corresponds to a notification of changes in significant share ownership, which maps to the Major Shareholding Notification category (MRQ). It is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-11-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.